Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2003-06-04
2010-10-19
Ketter, James S (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C435S235100, C435S462000
Reexamination Certificate
active
07816130
ABSTRACT:
Provided are novel vectors and viral vectors capable of expressing exogenous gene or exogenous nucleic acid sequences in a target cell of interest, such as T cells, bone marrow cells, epithelial cells, liver cells and the like. The nucleic acid components of the vectors may include one or more native promoter/enhancer regions having modified sequence segments, one or more non-native promoter/enhancer or non-native promoter's gene or gene segment, and a native viral vector terminator or processing signal or segment thereof. The viral vectors comprise a virus or viral portion having on the surfaces or envelopes adsorption components, one for a packaging cell line and the other for delivery to a target cell. Other viral vectors provided by this invention have two components on their surfaces or envelopes, one of which is native to the virus and the other being non-native and capable of adsorbing to the target cell while being incapable of adsorbing to a native cell for the viral vector. Packaging cell lines for propagating the vectors and viral vectors are also provided, as are novel processes for propagating any of the disclosed vectors or viral vectors.
REFERENCES:
patent: 5166320 (1992-11-01), Wu et al.
patent: 5278056 (1994-01-01), Bank et al.
patent: 5324643 (1994-06-01), Greatbatch et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5576201 (1996-11-01), Mason et al.
patent: 5650309 (1997-07-01), Wong-Staal et al.
patent: 5658776 (1997-08-01), Flotte et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5686279 (1997-11-01), Finer et al.
patent: 5702918 (1997-12-01), Bannwarth et al.
patent: 5750390 (1998-05-01), Thompson et al.
patent: 5750396 (1998-05-01), Yang et al.
patent: 5814500 (1998-09-01), Dietz et al.
patent: 5856152 (1999-01-01), Wilson et al.
patent: 5856185 (1999-01-01), Gruber et al.
patent: 5869331 (1999-02-01), Dornberg et al.
patent: 5929222 (1999-07-01), Lindemann et al.
patent: 6013517 (2000-01-01), Respess et al.
patent: 6111087 (2000-08-01), Rethwilm et al.
patent: 6271348 (2001-08-01), Bujard et al.
patent: 6333030 (2001-12-01), Curiel et al.
patent: 6432699 (2002-08-01), Meruelo et al.
patent: 6902929 (2005-06-01), Cichutek et al.
patent: 7494806 (2009-02-01), Liu et al.
patent: 0 128 332 (1984-12-01), None
patent: 0 779 365 (1997-06-01), None
patent: WO 95/06743 (1995-03-01), None
patent: WO9506743 (1995-03-01), None
patent: WO 96/13598 (1996-05-01), None
patent: WO 96/14332 (1996-05-01), None
patent: WO96/14332 (1996-05-01), None
patent: WO9613598 (1996-05-01), None
patent: WO 96/36705 (1996-11-01), None
patent: WO9636705 (1996-11-01), None
patent: WO 98/37917 (1998-09-01), None
patent: WO 98/42856 (1998-10-01), None
Paulus et al., J. Virol., 1996, vol. 70, No. 10, pp. 62-67.
Hofmann et al., PNAS, 1996, vol. 93, pp. 5185-5190.
Miller, et al.,Biotechniques, vol. 7(9):980-990 (1989).
Salmons, et al., “Targeting Retroviral Vectors for Gene Therapy,”Human Gene Therapy, vol. 4:129-141 (1993).
Van Den Wollenberg, D., et al,Gene, vol. 144(2):238-241 (1994).
Choulika, A., et al,Journal of Virology, vol. 70(3):1792-1798 (1996).
Ferrari, G., et al,Human Gene Therapy, vol. 6(6):733-742 (1995).
Lund, A.H., et al, “Transcriptional silencing of retroviral vectors,”Journal of Biomedical Science, vol. 3(6):365-378 (1996).
Robinson, D., et al,Gene Therapy, vol. 2(4):269-278 (1995).
Emi, H., et al., “Psudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus,”Journal of Virology 65:1202-1207 (1991).
Feng, M., et al., “Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector,”Nature Biotechnology 15:866-870 (1997).
Fisher, K.J., et al., “A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome,”Human Gene Therapy 7:2079-2087 (1996).
Gerhardt, E., et al., “Phenotype mixing of rodent but not avian hepadnavirus surface proteins into human hepatitis B virus particles,”Journal of Virology 69:1201-1208 (1995).
Johnston, K.M., et al., “HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells,”Human Gene Therapy 8:359-370 (1997).
Matano, T., et al., “Targeted infection of a retrovirus bearing a CD$-Env chimera into human cells expressing human immunodeficiency virus type 1,”Journal of General Virology 76:3165-3169 (1995).
Vile, R.G., et al., “A murine cell line producing HTLV-1 pseudotype virions carrying a selectable marker gene,”Virology 180:420-424 (1991).
Berkner,K.L., Curr. Top. Microbiol. Immunol., (1992), 158:39-66.
Emerman, M et al., Nucleic Acids Res.14:9381-9396, (1986).
Lewin, B. Genes V; Oxford University Press, New York (1994).
Sanbrook, J., Fritsch, E.F. and Maniatis, T. Molecular Cloning 2nd ed. Cold Spring Laboratory, Cold Spring Harbor, NY, 1989.
Rabbani E. et al., U.S. Appl. No. 08/574,443, filed Dec. 15, 1995 abandoned in favor of U.S. Appl. No. 08/978,632, filed Nov. 25, 1997.
Maddon, P.J. et al., Cell 47:333-348 (1986).
Robinson, William S., “Hepadnaviridae and Their Replication,” chapter in Field's Virology, vol. 2, edited by Fields, Bernard N., 2nd Edition, Ravens Press, pp. 2137-2169(1990).
Morgenstern, J.P. et al, “Choice and Manipulation of Retroviral Vectors,” Gene Transfer and Expression Protocols. Methods in Molecular Biology, vol. 7:181-193; (1991).
Anderson, W.F, “Human Gene Therapy,” Science 256:808-813 (1992).
Mulligan, R.C, “The Basic Science of Gene Therapy,” Science 260:926-932 (1993).
Smith, A.E, “Viral Vectors in Gene Therapy,” Ann Rev. Microbiol, 49:807-38 (1995).
Muzyczka, N, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,” Current Topics in Microbiolgy and Immunolgy 158:97-129 (1992).
Kotin, R.M, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,” Human Gene Therapy 5:793-801 (1994).
Emerman, M et al., “Genes with Promoters in Retrovirus Vectors Can Be Independently Suppressed by an Epigenetic Mechanism,” Cell 39:459-467 (1984).
Emerman, M et al., “Quantitative Analysis of Gene Suprression in Integrated Retrovirus Vectors,” Molecular and Cellular Biology 6(1):792-800 (1986).
Yu, S.F et al., “Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells,” Proc. Natl. Acad. Sci. USA 83:3194-3198 (1986).
Hawley, R.G. et al., “Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells,” Proc. Natl. Acad. Sci. USA 84; 2406-2410 (1987).
Yee, J.K et al., “Gene expression from transcriptionally disabled retroviral vectors,” Proc. Natl. Acad. Sci. USA 84:5197-5201 (1987).
Dougherty, J.P and Temin H.M., “A promoterless retroviral vector indicates that there are sequences in U3 required for 3′ RNA . . . ,” Proc. Natl. Acad. Sci. USA 84:1197-1201,1987.
Whitcomb, J.M and Hughes, S.H., “Retroviral Reverse Transcription and integration: Progress and Problems” Ann. Rev. Cell Biol. 8:275-306 (1992).
Jaenisch, R et al., “Germline Integration of Moloney Murine Leukemia Virus at the Mov13 Locus Leads to Recessive Lethal Mutation and Early Embryonic..,” Cell 32:209-216,1983.
Fung, Y.T. et al., “On the mechanism of retrovirus-induced avin lymphoid leucosis: Deletion and integration of the proviruses,” Proc. Natl, Acad, Sci. USA 78(6):3418-3422,1981.
Neel, B.G. and Hayward W.S., “Avian Leukosis Virus-Induced Tumors Have Common Proviral Integration Sites and Synthesize Discrete New RNAs: Oncogenesis . . . ”Cell 23:323-334,1981.
Payne, G.S. et al., “Analysis of Avian Leukosis Virus DNA and RNA in Bursal Tumors: Viral Gene Expression is Not Required for Maintenance of the Tumor..,” Cell 23:311-322,1983.
Samulski, R.J et al., “Targeted integration of adeno-associated virus (AA
Liu Dakai
Rabbani Elazar
Enzo Therapeutics, Inc.
Fedus, Esq. Ronald C.
Ketter James S
LandOfFree
Retroviral vectors expressing exogenous gene or exogenous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retroviral vectors expressing exogenous gene or exogenous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral vectors expressing exogenous gene or exogenous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195804